Path ID: DB06285_MESH_D015663_1

db06285-mesh-d015663-1

Concepts

Identifier Name Type
MESH:D019379 teriparatide Drug
UniProt:Q03431 Parathyroid hormone/parathyroid hormone-related peptide receptor Protein
GO:0004991 parathyroid hormone receptor activity MolecularActivity
GO:0001503 ossification BiologicalProcess
GO:0002076 osteoblast development BiologicalProcess
GO:0002062 chondrocyte differentiation BiologicalProcess
HP:0004349 Reduced bone mineral density Disease
MESH:D015663 Postmenopausal osteoporosis Disease

Relationships

NOTE: predicates are annotated in Biolink Model (v1.3.0)

Subject Predicate Object
Teriparatide INCREASES ACTIVITY OF Parathyroid Hormone/Parathyroid Hormone-Related Peptide Receptor
Parathyroid Hormone/Parathyroid Hormone-Related Peptide Receptor POSITIVELY REGULATES Parathyroid Hormone Receptor Activity
Parathyroid Hormone Receptor Activity POSITIVELY CORRELATED WITH Ossification
Parathyroid Hormone Receptor Activity POSITIVELY CORRELATED WITH Osteoblast Development
Parathyroid Hormone Receptor Activity POSITIVELY CORRELATED WITH Chondrocyte Differentiation
Parathyroid Hormone Receptor Activity POSITIVELY CORRELATED WITH Osteoblast Development
Ossification NEGATIVELY CORRELATED WITH Reduced Bone Mineral Density
Osteoblast Development NEGATIVELY CORRELATED WITH Reduced Bone Mineral Density
Chondrocyte Differentiation NEGATIVELY CORRELATED WITH Reduced Bone Mineral Density
Osteoblast Development NEGATIVELY CORRELATED WITH Reduced Bone Mineral Density
Reduced Bone Mineral Density POSITIVELY CORRELATED WITH Postmenopausal Osteoporosis

Comment: A right balance needs to be struck for normal bone formation, which involved bone resorption, the breaking down of bone tissue. This drug is actually a portion of the physiologically procuded hormone, PTH, which does increase bone resorption. So the right amount of drug (and frequency) is needed to be achieved to have a net effect of stimulating new bone formation therefore preventing osteoporosis.

Reference: